Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Zentalis Pharmaceuticals ( (ZNTL) ) has shared an announcement.
Zentalis Pharmaceuticals reported its third quarter 2025 financial results, highlighting significant progress in its DENALI Phase 2 trial for azenosertib, which remains on track with topline data expected by the end of 2026. The company is financially robust with $280.7 million in cash, supporting operations into late 2027, and has reduced its research and development expenses compared to the previous year, reflecting a strategic focus on advancing azenosertib’s development, potentially leading to accelerated FDA approval.
The most recent analyst rating on (ZNTL) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Zentalis Pharmaceuticals stock, see the ZNTL Stock Forecast page.
Spark’s Take on ZNTL Stock
According to Spark, TipRanks’ AI Analyst, ZNTL is a Neutral.
Zentalis Pharmaceuticals faces significant financial hurdles, with consistent losses and negative cash flows. Technical indicators also show weak momentum. However, recent positive clinical developments provide a glimmer of hope for future growth. Despite the financial and technical challenges, the potential of azenosertib in treating aggressive cancers could offer strategic value, albeit with high risk.
To see Spark’s full report on ZNTL stock, click here.
More about Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Diego, focused on developing azenosertib, a potentially first-in-class WEE1 inhibitor for Cyclin E1-positive platinum-resistant ovarian cancer (PROC) and other tumor types. The company is leveraging its expertise to explore additional opportunities for azenosertib beyond PROC.
Average Trading Volume: 762,810
Technical Sentiment Signal: Strong Sell
Current Market Cap: $92.33M
Learn more about ZNTL stock on TipRanks’ Stock Analysis page.